ClinicalTrials.gg
Active, not recruitingNCT05120349ADAURA2Updated Jul 6, 2026

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

A Phase 3 interventional study of Osimertinib and Placebo in Non-Small Cell Lung Cancer, sponsored by AstraZeneca. Active, not recruiting at 139 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
390
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung — 20 open to participants now, 43 under way, 8 of them phase 3. osimertinib · Carcinoma, Non-Small-Cell Lung.

Enrollment
8th of 90
390 · median 51
Started
2022
with 7 others
Phase 3
12 of 90
1 open now
Primary completion
2027-08
later than 28 of 42 live
Registered
67th of 90
by date
Lead sponsor
29 of 90
AstraZeneca

Among the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, this one is the 8th largest by enrollment, is one of 8 that started in 2022, is one of 12 in phase 3, reaches primary completion later than 28 of the 42 other live ones, and was the 67th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

20 of the 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung are open now, in 7 countries. Recruiting first, the newest first:

15 more — sign in →

By country, each count listing its studies:

All 20 open studies →

About osimertinib

osimertinib: first FDA approval 2015 (TAGRISSO), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing osimertinib in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a global study to assess the effects of osimertinib in participants with EGFRm stage IA2-IA3 non-small cell lung cancer following complete tumour resection.

Read the detailed description

This is a Phase III, double-blind, randomised, placebo-controlled, 2-arm, international study assessing the efficacy and safety of adjuvant osimertinib versus placebo in participants with stage IA2-IA3 EGFRm Non-Small Cell Lung Cancer, who have previously undergone complete tumour resection. All participants must have had a tumour which harbours one of the 2 common EGFR mutations known to be associated with EGFR-TKI sensitivity (Ex19del, L858R).

Eligible participants will be randomised in a 1:1 ratio to one of the 2 intervention arms: osimertinib 80 mg or matching placebo, once daily for 3 years unless discontinuation criteria is met.

03

Conditions studied

  • Non-Small Cell Lung Cancer

Keywords

  • Osimertinib
  • Tagrisso
  • NSCLC
  • Non-small Cell Lung Cancer
  • Resectable
  • EGFRm Positive
  • Adjuvant
  • Stage IA2-IA3
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, at least ≥ 18 years.
  2. NSCLC, of non-squamous histology.
  3. Stage IA2 or IA3 disease, based on TNM8 classification.
  4. Complete surgical resection (R0) of the primary NSCLC by lobectomy, bilobectomy, segmentectomy or sleeve resection.
  5. Complete recovery from surgery at the time of randomisation. Study intervention cannot commence within 4 weeks following surgery. No more than 12 weeks may have elapsed between surgery and randomisation for participants.
  6. World Health Organization performance status of 0 or 1.
  7. Provision of tumour sample for central pathology assessment of pathologic risk factors and to assess EGFR mutation status prior to randomisation.
  8. A tumour which harbours one of the 2 EGFR mutations (Ex19del, L858R) by cobas® EGFR Mutation Test v2 (Roche Diagnostics) or FoundationOne® test.
  9. Minimum of > 6 months.
  10. Females must be using highly effective measures, and must have a negative pregnancy test prior to start of dosing if of , or must have evidence of non-child-bearing potential. Male subjects must be willing to use barrier contraception.

Exclusion criteria

Exclusion Criteria

  1. Mixed small cell and non-small cell cancer history.
  2. Participants with incomplete (R1/R2) resection, or who have undergone pneumonectomy or only wedge resection.
  3. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension and active bleeding diatheses; or active infection including and or active uncontrolled infection.
  4. History of another primary , including any known or suspected synchronous primary lung cancer except for malignancy treated with curative intent with no known active disease ≥ 5 years before the first dose of study intervention and of low potential risk for recurrence.
  5. Any of the following cardiac criteria:

    • Mean resting interval > 470 ms, obtained from triplicate ECGs performed at screening.
    • Any abnormalities in rhythm, conduction, or morphology of resting ,
    • Any factors that increase the risk of QTcF prolongation or risk of arrhythmic events.
  6. History of interstitial lung disease.
  7. Inadequate bone marrow reserve or organ function.
  8. Any unresolved toxicities from prior therapy greater than Grade 1 at the time of starting study intervention.
  9. Prior treatment with any anticancer therapy for NSCLC (including chemotherapy, radiotherapy, immunotherapy, and EGFR-TKIs).
  10. Major surgery or significant traumatic injury within 4 weeks of the first dose of study intervention.
  11. Participants currently receiving medications or herbal supplements known to be strong inducers of .
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
390 participants (actual)

Study arms

  • Experimental
    Osimertinib

    Osimertinib 80mg, orally, once daily (Dose may be reduced to 40 mg once daily if required at the discretion of the investigator)

    Drug: Osimertinib

  • Placebo comparator
    Placebo

    Matching placebo for osimertinib, orally, once daily

    Drug: Placebo

Interventions

  • The initial dose of Osimertinib 80mg once daily can be reduced to 40mg once daily. Treatment can continue until disease recurrence, unacceptable toxicity or other discontinuation criteria are met.

    Also known as: AZD9291; TAGRISSO

  • DrugPlacebo

    Matching placebo. Initial dose of 80mg once daily can be reduced to 40mg once daily.

06

What researchers measure

Primary outcomes

  1. Disease-Free Survival (DFS) in high-risk stratum

    DFS is defined as the time from the date of randomisation until the date of disease recurrence or date of death (by any cause in the absence of recurrence), whichever occurs first. Stratification to the high risk stratum will be based on pathologic features assessed by central pathology review during screening.

    Time frame: From date of randomisation up to approximately 10 years

Secondary outcomes

  1. Disease-Free Survival (DFS) in overall population

    DFS is defined as the time from the date of randomisation until the date of disease recurrence or date of death (by any cause in the absence of recurrence), whichever occurs first.

    Time frame: From date of randomisation up to approximately 10 years

  2. Overall Survival (OS) in high-risk stratum and the overall population

    OS is defined as the time from the date of randomisation until death due to any cause.

    Time frame: From date of randomization up to approximately 10 years

  3. PK plasma concentrations of osimertinib and of metabolite AZ5104 in overall population

    Ratio of metabolite-to-osimertinib to be calculated at predose, and at 0.5-2 hours postdose.

    Time frame: From date of randomisation up to approximately 10 years

  4. Impact of osimertinib versus placebo on physical functioning

    Assess the impact of osimertinib versus placebo on physical functioning in both the high-risk stratum and the overall population as measured by SF-36 V2 health survey

    Time frame: From date of randomisation up to approximately 10 years

  5. Central Nervous System (CNS) Disease-Free Survival (DFS) in both the high-risk stratum and the overall population

    CNS DFS is defined as the time from randomisation to the time of a CNS lesion (as assessed by investigator) or death due to any cause, regardless of whether the participant withdraws from study intervention or receives other anti-cancer therapy.

    Time frame: From date of randomisation up to approximately 10 years

  6. Safety and tolerability in overall population

    AEs graded by CTCAE version 5.0

    Time frame: From date of randomisation up to approximately 10 years

07

Study locations

139 sites
  • Research Site
    Anchorage, Alaska 99508, United States
  • Research Site
    Los Angeles, California 90024, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    Grand Junction, Colorado 81501, United States
  • Research Site
    Newark, Delaware 19713, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    Chicago, Illinois 60612, United States
  • Research Site
    Frederick, Maryland 21702, United States
  • Research Site
    Morristown, New Jersey 07960, United States
  • Research Site
    Flushing, New York 11355, United States
  • Research Site
    New York, New York 10032, United States
  • Research Site
    New York, New York 10065, United States
  • Research Site
    White Plains, New York 10601, United States
  • Research Site
    Houston, Texas 77030, United States
  • Research Site
    Fort Belvoir, Virginia 22060, United States
  • Research Site
    Buenos Aires, C1431FWO, Argentina
  • Research Site
    CABA, C1012AAR, Argentina
  • Research Site
    Cipolletti, 8234, Argentina
  • Research Site
    La Plata, 1900, Argentina
  • Research Site
    Rosario, 2000, Argentina
  • Research Site
    Rosario, S2000CVB, Argentina
  • Research Site
    S.C. de Bariloche, 8400, Argentina
  • Research Site
    Barretos, 14784-400, Brazil
  • Research Site
    Belo Horizonte, 30380-090, Brazil
  • Research Site
    Porto Alegre, 90610-000, Brazil
  • Research Site
    Recife, 52010-075, Brazil
  • Research Site
    Rio de Janeiro, 22271-110, Brazil
  • Research Site
    São Paulo, 01327-001, Brazil
  • Research Site
    São Paulo, 04501-000, Brazil
  • Research Site
    Vancouver, British Columbia V5Z 1M9, Canada
  • Research Site
    Montreal, Quebec H4A 3J1, Canada
  • Research Site
    Toronto, M5G 2M9, Canada
  • Research Site
    Beijing, 100005, China
  • Research Site
    Beijing, 100029, China
  • Research Site
    Beijing, 100142, China
  • Research Site
    Beijing, 100210, China
  • Research Site
    Beijing, 100730, China
  • Research Site
    Beijing, 102218, China
  • Research Site
    Changchun, 130012, China
  • Research Site
    Changsha, 410013, China
  • Research Site
    Changsha, 430033, China
  • Research Site
    Chengdu, 610000, China
  • Research Site
    Fuzhou, 350014, China
  • Research Site
    Guangzhou, 510060, China
  • Research Site
    Guangzhou, 510100, China
  • Research Site
    Hangzhou, 310022, China
  • Research Site
    Harbin, 150049, China
  • Research Site
    Jinan, 250117, China
  • Research Site
    Nanjing, 210029, China
  • Research Site
    Shanghai, 200030, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Shenzhen, 518116, China
  • Research Site
    Suzhou, 215006, China
  • Research Site
    Taiyuan, 030000, China
  • Research Site
    Xi'an, 710061, China
  • Research Site
    Xintai, 54031, China
  • Research Site
    Yangzhou, 225001, China
  • Research Site
    Zhengzhou, 450008, China
  • Research Site
    Berlin, 13125, Germany
  • Research Site
    Esslingen am Neckar, 73730, Germany
  • Research Site
    Georgsmarienhütte, 49124, Germany
  • Research Site
    Lübeck, 23538, Germany
  • Research Site
    München, 81377, Germany
  • Research Site
    Würzburg, 97067, Germany
  • Research Site
    Bari, 70124, Italy
  • Research Site
    Catania, 95100, Italy
  • Research Site
    Florence, 50134, Italy
  • Research Site
    Genova, 16132, Italy
  • Research Site
    Milan, 20141, Italy
  • Research Site
    Naples, 80131, Italy
  • Research Site
    Padova, 35128, Italy
  • Research Site
    Parma, 43100, Italy
  • Research Site
    Roma, 00144, Italy
  • Research Site
    Chiba, 260-0877, Japan
  • Research Site
    Fukuoka, 812-8582, Japan
  • Research Site
    Hiroshima, 734-8551, Japan
  • Research Site
    Kashiwa, 227-8577, Japan
  • Research Site
    Kōtoku, 135-8550, Japan
  • Research Site
    Kyoto, 606-8507, Japan
  • Research Site
    Niigata, 951-8566, Japan
  • Research Site
    Osaka, 541-8567, Japan
  • Research Site
    Sakai, 590-0197, Japan
  • Research Site
    Sendai, 981-0914, Japan
  • Research Site
    Shinjuku-ku, 160-0023, Japan
  • Research Site
    Sunto-gun, 411-8777, Japan
  • Research Site
    Wakayama, 641-8510, Japan
  • Research Site
    Kuala Lumpur, 59100, Malaysia
  • Research Site
    Kuala Selangor, 46050, Malaysia
  • Research Site
    Kuching, 93586, Malaysia
  • Research Site
    Pulau Pinang, 10450, Malaysia
  • Research Site
    Poznan, 60-569, Poland
  • Research Site
    Warsaw, 01-138, Poland
  • Research Site
    Bucharest, 022328, Romania
  • Research Site
    Bucharest, 050098, Romania
  • Research Site
    Perm, 614990, Russia
  • Research Site
    Saint Petersburg, 191036, Russia
  • Research Site
    Singapore, 169610, Singapore
  • Research Site
    Singapore, 308433, Singapore
  • Research Site
    Daegu, 42415, South Korea
  • Research Site
    Jinju, 52727, South Korea

Showing the first 100 of 139 sites across 20 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Murat-Onana ML, Ramalingam SS, Janne PA, Gray JE, Ahn MJ, John T, Yatabe Y, Huang X, Rukazenkov Y, Javey M, Brown H, Li-Sucholeiki X. EGFR mutation testing across the osimertinib clinical program. Lung Cancer. 2025 Jun;204:108549. doi: 10.1016/j.lungcan.2025.108549. Epub 2025 Apr 18. PubMed 40311309 ↗

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved, AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Aug 2027, 65 months after the start.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 65 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2021
First posted
Nov 15, 2021
StartActual
Feb 21, 2022
Primary completionEst.
Aug 2, 2027
CompletionEst.
Nov 1, 2032
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05120349
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Nov 15, 2021
Start date
Feb 21, 2022
Primary completion
Aug 2, 2027 (estimated)
Completion
Nov 1, 2032 (estimated)
Last update
Jul 6, 2026

Study contacts

Jonathan Goldman, MD
principal investigator · University of California, Los Angeles
Yasuhiro Tsutani, MD, PhD
principal investigator · Kindai University Facility of Medicine
Jie He, MD, PhD
principal investigator · The Cancer Institute and Hospital, Chinese Academy of Medical Sciences (CAMS)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osimertinib

Start the discussion